Long
Interesting chart, possible breakout
Entasis Therapeutics Holdings, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products for serious drug-resistant bacterial infections. Its anti-infective discovery platform has produced a pipeline of differentiated programs, which is bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), Non-Beta-lactam PBP inhibitor, and Zoliflodacin. The company was founded in May 2015 and is headquartered in Waltham, MA.
Please note:
- I'm just sharing my view. its not a recommendation for buying or selling.
Please note:
- I'm just sharing my view. its not a recommendation for buying or selling.
“The fact is that if traders really believed that anything could happen at any time, there would be considerably fewer losers and more consistent winners.”
― Mark Douglas, Trading in the Zone
― Mark Douglas, Trading in the Zone
Declinazione di responsabilità
Le informazioni ed i contenuti pubblicati non costituiscono in alcun modo una sollecitazione ad investire o ad operare nei mercati finanziari. Non sono inoltre fornite o supportate da TradingView. Maggiori dettagli nelle Condizioni d'uso.
“The fact is that if traders really believed that anything could happen at any time, there would be considerably fewer losers and more consistent winners.”
― Mark Douglas, Trading in the Zone
― Mark Douglas, Trading in the Zone
Declinazione di responsabilità
Le informazioni ed i contenuti pubblicati non costituiscono in alcun modo una sollecitazione ad investire o ad operare nei mercati finanziari. Non sono inoltre fornite o supportate da TradingView. Maggiori dettagli nelle Condizioni d'uso.